Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal (Q38534132)

3 September 2017

1 reference

title

Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal (English)

1 reference

3 September 2017

0 references

0 references

Carmela Leone

1 reference

3 September 2017

Cinzia Caserta

series ordinal

1 reference

3 September 2017

Francesco Patti

series ordinal

1 reference

3 September 2017

language of work or name

1 reference

22 June 2015

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

3 September 2017

published in

1 reference

3 September 2017

1 reference

3 September 2017

1 reference

3 September 2017

page(s)

803-824

1 reference

Is it time for a new global classification of multiple sclerosis?

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Defining the clinical course of multiple sclerosis: the 2013 revisions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Update on disease-modifying treatments for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

The immune modulator FTY720 targets sphingosine 1-phosphate receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Oral fingolimod (FTY720) for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Does natalizumab therapy worsen neuromyelitis optica?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Unmasking and provoking severe disease activity in a patient with NMO spectrum disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

The Sphingosine-1-phospate receptor 1 mediates S1P action during cardiac development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Fingolimod therapy for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Sudden unexpected death on fingolimod.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Activation of the SPHK/S1P signalling pathway is coupled to muscarinic receptor-dependent regulation of peripheral airways

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Pulmonary and vascular pharmacology of sphingosine 1-phosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Fingolimod treatment in multiple sclerosis leads to increased macular volume

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Higher macular volume in patients with MS receiving fingolimod: positive outcome or side effect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

A review of safety-related pregnancy data surrounding the oral disease-modifying drugs for multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Fingolimod after natalizumab and the risk of short-term relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Relapses in patients treated with fingolimod after previous exposure to natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Teriflunomide and its mechanism of action in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Mechanism of action for leflunomide in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Teriflunomide: a review of its use in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Randomized trial of oral teriflunomide for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Solving the dilemma of EEG misinterpretation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

21 January 2018

New hands at the helm

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Teriflunomide in relapsing multiple sclerosis: therapeutic utility

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

A Heteroskedasticity-Consistent Covariance Matrix Estimator and a Direct Test for Heteroskedasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Leflunomide-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Pharmacokinetics of oral fumarates in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Glial cells express nuclear nrf2 after fumarate treatment for multiple sclerosis and psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Dimethylfumarate is a potent inducer of apoptosis in human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Mode of action and clinical studies with fumarates in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Fumarate treatment in progressive forms of multiple sclerosis: first results of a single-center observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Fatal PML associated with efalizumab therapy: insights into integrin αLβ2 in JC virus control

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Peripheral neuropathy due to dinitrophenol used for weight loss: something old, something new.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Efficacy and safety of laquinimod in multiple sclerosis: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Laquinimod suppress antigen presentation in relapsing-remitting multiple sclerosis: in-vitro high-throughput gene expression study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Placebo-controlled trial of oral laquinimod for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Cladribine: mode of action and implications for treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Cladribine for multiple sclerosis: review and current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Beyond hairy cell: the activity of cladribine in other hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Development of oral cladribine for the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

The treatment of chronic progressive multiple sclerosis with cladribine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Cladribine in treatment of chronic progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Freedom from disease activity in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Exposure-disease continuum for 2-chloro-2'-deoxyadenosine (2-CdA), a prototype teratogen: induction of lumbar hernia in the rat and species comparison for the teratogenic responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Highly selective and potent agonists of sphingosine-1-phosphate 1 (S1P1) receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Efficacy and immunomodulatory actions of ONO-4641, a novel selective agonist for sphingosine 1-phosphate receptors 1 and 5, in preclinical models of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

The Selective Sphingosine 1-Phosphate Receptor 1 Agonist Ponesimod Protects against Lymphocyte-Mediated Tissue Inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Leukocyte counts in cerebrospinal fluid and blood following firategrast treatment in subjects with relapsing forms of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Cognitive impairment and "invisible symptoms" are not associated with CCSVI in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Towards the implementation of 'no evidence of disease activity' in multiple sclerosis treatment: the multiple sclerosis decision model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Retinal nerve fibre layer thickness correlates with brain white matter damage in multiple sclerosis: a combined optical coherence tomography and diffusion tensor imaging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Multiple sclerosis and pregnancy prescriptions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

Expert recommendations to personalization of medical approaches in treatment of multiple sclerosis: an overview of family planning and pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.2015.1058162

10.1586/14737175.2015.1058162

21 January 2018

Identifiers

DOI

1 reference

3 September 2017

1 reference